Inland Rheumatology Clinical Trials, Inc | Upland, CA

Research site

(Unclaimed)

Location

1238 E. Arrow Highway, Upland, California, United States of America

Site insights

Top conditions

Top treatments

Litifilimab

BIIB059

GLPG3667

Dazodalibep

VIB7734

Certolizumab

Secukinumab

KPL-404

SAR441566

Obinutuzumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 16 total trials

Locations recently updated

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling

Sjögren's Syndrome (SS)

Drug: Dazodalibep

Drug: Placebo

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling

Systemic Lupus Erythematosus

Drug: GLPG3667

Drug: Placebo

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered...

Enrolling

Dermatomyositis

Drug: Placebo

Drug: GLPG3667

A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: BIIB059 (litifilimab)

Drug: Placebo

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis (SPECIFI-RA)

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling

Rheumatoid Arthritis

Drug: SAR441566

Drug: Placebo

A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD)

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only

Systemic Lupus Erythematosus (SLE)

Drug: Litifilimab-matching placebo

Drug: Litifilimab

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling

Sjogren's Syndrome

Drug: Dazodalibep

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus (ALLEGORY)

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with...

Enrolling

Systemic Lupus Erythematosus

Drug: Methylprednisolone

Drug: Acetaminophen/Paracetamol

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (DAISY)

The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.

Active, not recruiting

Arthritis, Rheumatoid

Drug: Placebo

Drug: Nipocalimab

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-1)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling

Lupus Erythematosus, Systemic

Drug: Litifilimab

Drug: Placebo

Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the...

Enrolling

Autoimmunity, Inflammation

Biological: Secukinumab s.c. injection

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE)...

Enrolling

Cutaneous Lupus Erythematosus (CLE)

Drug: Edecesertib

Drug: Edecesertib Placebo

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Active, not recruiting

Rotator Cuff Tendinopathy

Drug: Secukinumab

Drug: Placebo